ADHD
Peptides explored for ADHD — Semax, Selank — with honest framing about Russian clinical use, why stimulants remain first-line, and where peptide therapy might add value as an adjunct.
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental condition characterized by inattention, hyperactivity, and impulsivity that significantly impairs functioning. ADHD affects roughly 5-7% of children and 4-5% of adults globally. The diagnosis requires symptoms beginning in childhood, persistence into adulthood for adult diagnoses, and meaningful functional impairment across multiple settings (school, work, home, social). Conventional management combines pharmacotherapy (stimulants — methylphenidate, amphetamines — as first-line, with non-stimulant alternatives atomoxetine, viloxazine, guanfacine, clonidine) and behavioral and cognitive interventions (parent training in children, executive function coaching in adults, environmental modifications).
Peptide therapy for ADHD is discussed primarily in the context of Semax, the synthetic ACTH(4-10) analog developed at the Russian Academy of Sciences. Semax has been used clinically in Russia for cognitive and attentional conditions including ADHD, with available evidence largely from Russian clinical literature. Selank may have a complementary role for the anxiety and emotional regulation component that frequently accompanies ADHD. The honest framing: peptides do not replace stimulant or non-stimulant ADHD medications, particularly for moderate-to-severe symptoms with significant functional impairment. Where peptide therapy might add value is as an adjunct for cognitive support and emotional regulation, particularly in patients also engaged with appropriate pharmacological and behavioral care.
This page covers what's actually known about peptides for ADHD, the boundaries with conventional stimulant therapy, and important caveats. It is informational, not medical advice.
Peptides discussed for ADHD
N-Acetyl Selank Amidate
Nootropic Peptide
An enhanced version of Selank with improved stability, studied for anxiety reduction and cognitive enhancement.
Selank
Nootropic Peptide
A synthetic peptide analog of tuftsin with anxiolytic and nootropic properties, developed in Russia.
Semax
Nootropic Peptide
A synthetic peptide analog of ACTH(4-10) developed in Russia, studied for cognitive enhancement and neuroprotection.
Dihexa
Angiotensin Analog
A potent angiotensin IV analog studied for cognitive enhancement. Its Dihexa-derived prodrug fosgonimeton failed its Phase 2/3 Alzheimer's trial (LIFT-AD, 2024), and the foundational 2014 HGF/c-Met mechanism paper was retracted in 2025 — material context that reshapes how the preclinical literature should be read.
NA-Semax-Amidate
Nootropic Peptide
A chemically modified version of Semax designed for improved stability. No published clinical or preclinical data exists for this specific compound.
How peptides target adhd
Semax modulates dopaminergic and serotonergic neurotransmission, the same neurotransmitter systems targeted by stimulant ADHD medications. The mechanism — enhanced BDNF expression, neurotrophic support of attention and memory networks, modulation of monoamines — aligns with the neurobiology of ADHD. Russian clinical use includes ADHD-related applications, primarily in pediatric populations, with reported benefits for attention, working memory, and learning. The active form is most often discussed as nasal spray, allowing intranasal-to-CNS delivery.
Selank may have a complementary role for the anxiety component of ADHD. Anxiety frequently accompanies ADHD (estimated 25-50% comorbid anxiety) and contributes to functional impairment. Selank's anxiolytic mechanism without sedation aligns with the goal of reducing anxiety while preserving the cognitive and attentional engagement essential for ADHD management.
What peptides do not do for ADHD: replicate the rapid and substantial cognitive and attentional improvements of stimulant medication; address the dopamine and norepinephrine signaling abnormalities that drive ADHD biology in the validated way that methylphenidate or amphetamines do; resolve severe functional impairment in moderate-to-severe ADHD without primary therapy.
What the evidence shows
There are no Western randomized trials of Semax or Selank for ADHD specifically. Russian clinical literature describes use in pediatric attention and learning conditions but does not meet Western pivotal-trial standards. Western preclinical work on Semax has explored cognitive and neurotrophic mechanisms.
For evidence-validated comparators in ADHD, the trial base is enormous. Methylphenidate and amphetamines have hundreds of RCTs in ADHD with effect sizes (Cohen's d 0.8-1.0+) substantially larger than most psychiatric medications. Atomoxetine, viloxazine, guanfacine, and clonidine provide non-stimulant alternatives with established evidence. Behavioral parent training has strong evidence in pediatric ADHD. Cognitive-behavioral therapy adapted for ADHD shows benefit in adult populations.
Peptide therapy does not approach this evidence base. The reasonable place for peptides is as an adjunct in selected patients — for example, patients with comorbid anxiety where Selank may help, or patients seeking cognitive support beyond what stimulant medication alone provides — under qualified clinical supervision.
Important caveats
ADHD diagnosis and management should be coordinated by a clinician familiar with ADHD — psychiatrist, behavioral pediatrician, neurologist, or experienced primary care clinician. Self-diagnosed ADHD without proper evaluation leads to both over-treatment of normal variation and under-treatment of true ADHD. Stimulant medications remain first-line for ADHD with substantial RCT evidence; non-stimulant alternatives are appropriate for patients who do not tolerate or respond to stimulants.
Semax and Selank are Russian-approved only and not FDA-approved. Sourcing through research-chemical channels has the typical concerns about identity, purity, and concentration. Peptide therapy without engagement with conventional ADHD evaluation and treatment risks under-treatment of a condition with substantial functional and developmental consequences when untreated, particularly in pediatric populations.
Monitoring requirements for pediatric and adult ADHD are significant: response assessment, side effect monitoring, growth tracking in children on stimulants, cardiovascular monitoring as appropriate. Self-directed peptide use without these is inappropriate. WADA-tested athletes should be aware that some ADHD medications are prohibited in competition — Semax and Selank are not currently named on the WADA list but the S0 'non-approved substances' clause may apply.
Frequently asked questions
Can peptides replace ADHD stimulants?
No. Stimulant medications (methylphenidate, amphetamines) have substantial RCT evidence in ADHD with effect sizes substantially larger than most psychiatric medications. No peptide has demonstrated efficacy comparable to stimulants for ADHD core symptoms. Peptides may be a reasonable adjunct for selected patients, but they should not be expected to substitute for stimulant therapy in patients who need it.
What is the best peptide for ADHD?
Semax has the most mechanistically aligned role for ADHD-relevant cognitive and attentional support, with Russian clinical use base. Selank may help with the anxiety component that frequently accompanies ADHD. None has Western RCT validation specifically for ADHD. The right framing: peptides may be adjuncts to evidence-validated ADHD treatment, not standalone primary therapy.
Are peptides safe for children with ADHD?
Pediatric peptide use has limited safety data in any indication. Russian clinical use includes pediatric Semax for cognitive applications, but the data does not meet Western standards for pediatric drug safety. Pediatric ADHD should be managed by clinicians familiar with childhood ADHD with appropriate evidence-based therapy. Self-directed peptide use in children is inappropriate.
Will Semax help with focus and concentration in adult ADHD?
Possibly, based on Russian clinical use base and mechanistic plausibility. Effects in adult ADHD have not been validated in Western RCTs. Adults with significant functional impairment from ADHD generally benefit substantially from stimulant or non-stimulant ADHD medication; adding Semax as a cognitive support adjunct may have modest additional benefit but should not substitute for primary therapy.
What about peptides for anxiety in ADHD?
Selank has Russian clinical evidence for anxiolytic effects without the sedation, tolerance, or dependence of benzodiazepines. The anxiety component of ADHD (comorbid in 25-50% of patients) often contributes substantially to functional impairment. Selank may be a reasonable adjunct in patients with both ADHD and anxiety who are also engaged with primary ADHD treatment. Conventional anxiety treatment (SSRIs, CBT) has stronger evidence and should generally be considered first.
Part of these goals
Related conditions
Stacks that overlap
- Semax + Selank (The Nootropic Stack)
The Russian nootropic peptide combination — Semax for cognitive enhancement and BDNF upregulation paired with Selank for anxiolytic effects and stress resilience.
Updated 2026-05-08